ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Clinical Trial: CTMX-M-2029-001

Trial Status: Open
Disease Type: Lymphoma
Trial ID CTMX-M-2029-001
Sponsor ID CTMX-M-2029-001

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location

Locations

Fairfax Office

Learn More About This Trial
Other Relevant Trials
Trial ID 18263
Sponsor ID Beigene

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Principal Investigator
Mitul Gandhi, MD
5 Locations
Trial ID 18013
Sponsor ID Seattle Genetics, Inc.

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects .  Ph2 A+AVD +G-CSF or AOAD in CHL

Principal Investigator
Mitul Gandhi, MD
5 Locations